Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBAOTCMKTS:CSLLYNYSE:GSKNYSE:GSK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.56-2.5%$2.63$0.80▼$4.08$934.98M0.853.18 million shs6.47 million shsCSLLYCSL$77.54-2.0%$78.24$70.22▼$109.00$75.09B0.891,040 shs87,864 shsGSKGSK$40.82-3.9%$38.09$31.72▼$44.67$83.66B0.524.86 million shs7.66 million shsGSKGSK$40.82-3.9%$38.09$31.72▼$44.67$83.66B0.524.86 million shs7.66 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-10.33%+36.40%+48.33%+232.71%CSLLYCSL0.00%-1.80%-0.09%-2.80%-18.58%GSKGSK0.00%-0.98%+8.46%+1.28%+0.41%GSKGSK0.00%-0.98%+8.46%+1.28%+0.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.0068 of 5 stars3.62.00.04.03.20.80.6CSLLYCSL0.8441 of 5 stars0.03.01.70.01.10.01.3GSKGSK1.7237 of 5 stars1.14.02.50.02.10.01.9GSKGSK1.7237 of 5 stars1.14.02.50.02.10.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.7589.61% UpsideCSLLYCSL 4.00Strong BuyN/AN/AGSKGSK 2.27Hold$37.38-8.44% DownsideGSKGSK 2.27Hold$37.38-8.44% DownsideCurrent Analyst Ratings BreakdownLatest AKBA, CSLLY, GSK, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.006/3/2025GSKGSKBerenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold6/3/2025GSKGSKBerenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/28/2025AKBAAkebia TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025AKBAAkebia TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.004/28/2025GSKGSKHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell4/28/2025GSKGSKHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell4/15/2025GSKGSKBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$35.254/15/2025GSKGSKBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$35.254/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/1/2025AKBAAkebia TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$184.91M5.06N/AN/A($0.16) per share-22.25CSLLYCSL$14.80B5.07$3.73 per share20.80$20.07 per share3.86GSKGSK$31.53B2.65$6.46 per share6.32$8.07 per share5.06GSKGSK$31.53B2.65$6.46 per share6.32$8.07 per share5.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.21N/AN/AN/A-27.07%N/A-20.57%8/6/2025 (Estimated)CSLLYCSL$2.64BN/A0.0018.961.59N/AN/AN/A8/19/2025 (Estimated)GSKGSK$3.29B$1.9425.678.781.128.13%48.59%11.11%7/30/2025 (Estimated)GSKGSK$3.29B$1.9425.678.781.128.13%48.59%11.11%7/30/2025 (Estimated)Latest AKBA, CSLLY, GSK, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million4/30/2025Q1 2025GSKGSK$1.08$1.13+$0.05$1.00$7.52 billion$10.06 billion4/30/2025Q1 2025GSKGSK$1.08$1.13+$0.05$1.00$7.52 billion$10.06 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ACSLLYCSL$1.201.55%N/AN/AN/AGSKGSK$1.684.12%N/A86.60%N/AGSKGSK$1.684.12%N/A86.60%N/ALatest AKBA, CSLLY, GSK, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025GSKGSKquarterly$0.42164.1%5/16/20255/16/20257/10/20255/2/2025GSKGSKquarterly$0.42164.1%5/16/20255/16/20257/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.521.21CSLLYCSL0.582.180.97GSKGSK1.120.780.52GSKGSK1.120.780.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%CSLLYCSL0.03%GSKGSK15.74%GSKGSK15.74%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%CSLLYCSLN/AGSKGSK10.00%GSKGSK10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million209.24 millionOptionableCSLLYCSL30,000968.42 millionN/ANot OptionableGSKGSK90,1002.05 billion1.87 billionOptionableGSKGSK90,1002.05 billion1.87 billionOptionableAKBA, CSLLY, GSK, and GSK HeadlinesRecent News About These CompaniesNICE approves GSK’s belantamab mafodotin for blood cancerJune 16 at 6:37 AM | finance.yahoo.comGSK plc (NYSE:GSK) Shares Acquired by Hennessy Advisors Inc.June 15 at 5:27 AM | marketbeat.comGSK says EU regulator reviewing expanded use of RSV vaccineJune 14 at 1:03 AM | msn.comGSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And OlderJune 13 at 2:59 PM | finance.yahoo.comBharat Biotech acquires licence for GSK’s Shigella vaccine developmentJune 13 at 9:58 AM | pharmaceutical-technology.comGSK plc (NYSE:GSK) Stock Holdings Boosted by Thomasville National BankJune 13 at 6:03 AM | marketbeat.comGSK seeks broader European approval for RSV vaccineJune 13 at 5:01 AM | proactiveinvestors.co.ukGSK says EU heath regulator reviewing expansion of RSV vaccineJune 13 at 2:14 AM | reuters.comBharat Biotech in-licenses GSK vaccine candidate for bacterial diarrhoeaJune 12, 2025 | fortuneindia.comBharat Biotech, GSK Develop Shigellosis VaccineJune 12, 2025 | money.rediff.comBharat Biotech and GSK Unite for Groundbreaking Shigellosis VaccineJune 12, 2025 | devdiscourse.comBharat Biotech signs pact with GSK to develop Shigella vaccine candidateJune 12, 2025 | business-standard.comBharat Biotech, GSK partner to develop vaccine for Shigella diarrhoeaJune 12, 2025 | business-standard.comBharat Biotech, GSK team up to develop Shigella vaccine for global healthJune 12, 2025 | thehindubusinessline.comCohen Klingenstein LLC Has $3.08 Million Stake in GSK plc (NYSE:GSK)June 11, 2025 | marketbeat.comGSK plc (NYSE:GSK) Shares Bought by Bard Financial Services Inc.June 11, 2025 | marketbeat.comMADDEN SECURITIES Corp Has $4.14 Million Holdings in GSK plc (NYSE:GSK)June 10, 2025 | marketbeat.comPark Avenue Securities LLC Buys 25,111 Shares of GSK plc (NYSE:GSK)June 10, 2025 | marketbeat.comSanofi’s Sanjay Gurunathan poached by GSKJune 9, 2025 | thepharmaletter.comGSK snags long-time Sanofi exec to lead vaccine and infectious disease R&DJune 9, 2025 | fiercebiotech.com20,775 Shares in GSK plc (NYSE:GSK) Bought by Merit Financial Group LLCJune 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKBA, CSLLY, GSK, and GSK Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.56 -0.09 (-2.47%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.56 +0.00 (+0.03%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.CSL OTCMKTS:CSLLY$77.54 -1.60 (-2.02%) As of 06/13/2025 03:59 PM EasternCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.GSK NYSE:GSK$40.82 -1.67 (-3.94%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$41.18 +0.36 (+0.89%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.GSK NYSE:GSK$40.82 -1.67 (-3.94%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$41.18 +0.36 (+0.89%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
